10 results
8-K
EX-99.1
VERV
Verve Therapeutics Inc
27 Feb 24
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
7:45am
the collaboration agreement with Vertex.
R&D Expenses: Research and development (R&D) expenses were $46.8 million for the quarter ended December 31, 2023, and $184.9
8-K
EX-99.1
VERV
Verve Therapeutics Inc
7 Nov 23
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
7:00am
to research services performed under the collaboration agreement with Vertex.
Research & Development (R&D) Expenses: R&D expenses were $43.8 million
8-K
EX-99.1
VERV
Verve Therapeutics Inc
10 Aug 23
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
7:00am
Pharmaceuticals Incorporated. There was no collaboration revenue in the second quarter of 2022.
Research & Development (R&D) Expenses: R&D expenses were $47.3
8-K
EX-99.1
VERV
Verve Therapeutics Inc
15 May 23
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
7:00am
revenue in the first quarter of 2022.
Research & Development (R&D) Expenses: R&D expenses were $47.1 million for the first quarter of 2023, compared
8-K
EX-99.1
VERV
Verve Therapeutics Inc
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
to be sufficient to fund the company’s current operating plan into the second half of 2025.
Research & Development (R&D) Expenses: R&D expenses were
8-K
EX-99.1
gqh039
9 Aug 22
Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
6:45am
8-K
EX-99.1
ul7 w9tcv
10 May 22
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023
6:48am
8-K
EX-99.1
fq9649tscpjp p5
14 Mar 22
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
6:49am
8-K
EX-99.1
bmhon fx7w
10 Nov 21
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
6:56am
8-K
EX-99.1
ge2hm xmz59e8xfo
12 Aug 21
Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
8:20am
- Prev
- 1
- Next